Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid and advanced skin cancer. This FDA recap highlights recent approvals in April ...

Panelists discuss the promising results of the ReNeu trial for mirdametinib, highlighting its significant tumor shrinkage and ...

The novel dosage forms are distinguished by technology-based, specialty uses, providing benefits such as improved patient convenience, improved dosing compliance, ...

TORONTO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and ...

TORONTO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla” or the "Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and ...

(2025-02-27 | CSE:MDMA) PharmAla to supply STRONG STAR at UT Health San Antonio, with novel dosage form of LaNeo(TM) MDMA Stockhouse.com uses cookies on this site. By continuing to use our service, ...

TORONTO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research ...